Are We Nearing the End of 12-Month DAPT Following PCI?

Short-term DAPT followed by ticagrelor monotherapy did not increase ischemic events and reduced bleeding risk in the first year after PCI.

While the most recent U.S. guidelines recommend a shortened duration of dual antiplatelet therapy (DAPT) of 1 to 3 months following percutaneous coronary intervention (PCI; Circulation 2022; 145:e18), there is less evidence for shortened DAPT when PCI is performed for acute coronary syndromes (ACS; Eur Heart J 2023; 44:3720).

Researchers performed a systematic review and individual participant–level meta-analysis of randomized trials to compare the efficacy and safety of short-term DAPT (for 2 weeks to 3 months) followed by ticagrelor 90 mg twice daily versus 12-month DAPT following PCI with coronary stent placement. Trials including participants requiring long-term oral anticoagulation were excluded.

Six trials with approximately 23,000 part…

Reviewing Author

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Are We Nearing the End of 12-Month DAPT Following PCI?

Topics

Reviewing Author